Abstract:Abstract Background Colchicine is a widely used drug to treat inflammatory diseases. Due to its long historical use in medicine, controlled clinical trials have been small and there remains some caution with the use of this drug in patients with co-morbidities. The aim of the study is to systematically examine the side effect profile of colchicine in controlled clinical trials across all published indications. Methods A systematic review was conducted in accordance with PRISMA methodology. The Cochrane Library, MEDLINE and EMBASE were searched for double-blind controlled trials of oral colchicine in adult patients that reported adverse event data. Meta-analyses were used to determine the relative risk (RR) of adverse events in colchicine users compared to comparator groups. Results A total of 4915 studies were initially identified and after exclusions, 35 randomised controlled trials with placebo ( n = 30) or active comparators ( n = 5) were included. The most common diseases studied were gout, liver cirrhosis and pericarditis. There were a total of 8659 pooled participants, 4225 participants were randomised to receive colchicine, 3956 to placebo and 411 to an active comparator. Diarrhoea was reported in 17.9% of colchicine users versus 13.1% in comparator groups (RR 2.4, 95% confidence interval (CI) 1.6, 3.7). Any gastrointestinal event was reported in 17.6% of colchicine users and 13.1% of comparators (RR 1.7, 95% CI 1.3, 2.3). Adverse liver events were reported in 1.9% of colchicine users versus 1.1% in the comparator groups (RR 1.6, 95% CI 0.9, 3.0). Muscle events were reported in 4.2% of colchicine users and 3.3% in the comparator groups (RR 1.3, 95% CI 0.8, 1.9). Haematology events were reported in 0.6% of colchicine users and 0.4% of comparator groups (RR 1.34 (0.64, 2.82). No study reported neuropathy events. Other sensory events were reported in 1.1% of colchicine users and 1.5% of comparator groups (RR 1.4, 95% CI 0.3, 6.7). Infectious events were reported in 0.4% of colchicine users and 2.1% of comparator groups (RR 1.0, 95% CI 0.7, 1.5). No study reported death as an adverse event. Conclusion Colchicine increases the rate of diarrhoea and gastrointestinal adverse events but does not increase the rate of liver, sensory, muscle, infectious or haematology adverse events or death.

S3108 Rhabdomyolysis with Diarrhea: A Rare Case of Colchicine Toxicity

A Fatal Colchicine Ingestion With Antemortem Blood Concentration

Delayed elimination in humans after ingestion of colchicine: Two fatal cases of colchicine poisoning

Colchicine-Induced Acute Neuromyopathy in a Patient Using Concomitant Fluconazole: Case Report and Literature Review

Near fatal acute colchicine intoxication in a child. A case report

Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials

Colchicine Overdose in a Suicidal Attempt

Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)

A systematic review of the drug–drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies

Colchicine in Renal Medicine: New Virtues of an Ancient Friend

Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management

Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning.

Leukopenia associated with long-term colchicine administration.

Histopathology of acute colchicine intoxication: novel findings and their association with clinical manifestations

Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature

Dynamic Observation of Bone Marrow Suppression and Chromosomal Aberrations in Patients with Acute Colchicine Poisoning

The perils of Grandma's medication: colchicine toxicity causing pneumomediastinum.

Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system

Colchicine disrupts bile acid metabolic homeostasis by affecting the enterohepatic circulation in mice

Colchicine for cardiovascular medicine: a systematic review and meta-analysis

Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease